Evidence map›Paper›PMID 30361796›Full record

ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2019

Contribution of the GSTP1 c.313A>G variant to hearing loss risk in patients exposed to platin chemotherapy during childhood.

P H P Liberman, M V S Goffi-Gomez, C Schultz, P L Jacob, C A A de Paula, E L Sartorato, G T Torrezan, E N Ferreira, D M Carraro

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.5field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

P H P LibermanAudiology Department, AC Camargo Cancer Center, r. Antonio Prudente, 211, São Paulo, 01509-900, Brazil.
M V S Goffi-GomezAudiology Department, AC Camargo Cancer Center, r. Antonio Prudente, 211, São Paulo, 01509-900, Brazil. goffigomez@uol.com.br.ORCID http://orcid.org/0000-0002-4440-7692
C SchultzAudiology Department, AC Camargo Cancer Center, r. Antonio Prudente, 211, São Paulo, 01509-900, Brazil.
P L JacobHuman Molecular Genetics Laboratory, Molecular Biology and Genetic Engineering Center, CBMEG, State University of Campinas (UNICAMP), Campinas, Brazil.
C A A de PaulaGenomics and Molecular Biology Laboratory, International Research Center/CIPE, AC Camargo Cancer Center, São Paulo, Brazil.
E L SartoratoHuman Molecular Genetics Laboratory, Molecular Biology and Genetic Engineering Center, CBMEG, State University of Campinas (UNICAMP), Campinas, Brazil.
G T TorrezanGenomics and Molecular Biology Laboratory, International Research Center/CIPE, AC Camargo Cancer Center, São Paulo, Brazil.
E N FerreiraGenomics and Molecular Biology Laboratory, International Research Center/CIPE, AC Camargo Cancer Center, São Paulo, Brazil.
D M CarraroGenomics and Molecular Biology Laboratory, International Research Center/CIPE, AC Camargo Cancer Center, São Paulo, Brazil.
AC Camargo Hospital · BRUniversidade Estadual de Campinas (UNICAMP) · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

aimOtotoxicity is a potential adverse effect of chemotherapy with platin drugs, such as cisplatin and carboplatin, in children. Hearing loss (HL) affecting frequencies below 4 kHz can compromise speech perception. The aim of this study was to investigate whether genetic variants previously implicated in ototoxicity are associated with HL overall and HL below 4 kHz in pediatric oncology patients treated with cisplatin or carboplatin. MATERIALS AND

methodsPatients given cisplatin or carboplatin for a pediatric cancer at least 5 years prior to the start of the study were enrolled. The patients underwent comprehensive audiological evaluations and genotyping to detect the presence of the GJB2 c.35delG, GSTP1 c.313A>G, and MT-RNR1 m.1555A>G polymorphisms.

resultsHL was identified in 31/61 patients (50.8%), including 28/42 treated with cisplatin (66.6%) and 3/19 treated with carboplatin (15.8%). HL was associated with higher mean doses of cisplatin (p = .002) and carboplatin (p = .010). The c.313A>G variant of GSTP1 (heterozygous or homozygous) was detected in 31/61 patients (50.8%). An association between this variant allele and HL involving frequencies ≤ 4 kHz was identified (p = .020; 10-fold vs. non-carriers). No associations with HL were observed for GJB2 or MT-RNR1 gene variants.

conclusionThe GSTP1 c.313A>G variant may increase the risk of low-frequency HL in pediatric oncology patients treated with cisplatin or carboplatin chemotherapy.

Indexed as

Polymorphism, GeneticAntineoplastic Combined Chemotherapy ProtocolsCarboplatinChildChild, PreschoolCisplatinFemaleFollow-Up StudiesGlutathione S-Transferase piHearing LossHumansMaleNeoplasmsPrognosisProspective StudiesCarboplatinCisplatinGlutathione S-Transferase piGSTP1 protein, humanCancerCarboplatinCisplatinGSTP1Hearing lossOtotoxicity

Identifiers

PMID30361796
OpenAlexW2898571487

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.